4 published verifications about Oral Contraceptive Pill Oral Contraceptive Pill ×
“The oral contraceptive pill universally reduces sexual desire in all women who take it.”
The evidence decisively contradicts this claim. Systematic reviews show approximately 84.6% of oral contraceptive users report no change in sexual desire, and about 12% actually report an increase — only a small minority experience a decrease. While reduced libido is a real, documented side effect for some women, the claim's absolute language — "universally" and "all women" — is unsupported by any credible source. The pill's effects on desire are highly variable and individual.
“Use of the oral contraceptive pill causes long-term or permanent infertility after discontinuation.”
Overwhelming medical evidence directly contradicts this claim. The World Health Organization, systematic reviews, and large cohort studies all confirm that oral contraceptive use — regardless of duration — does not cause long-term or permanent infertility, with fertility returning promptly after discontinuation. Some women may experience temporary cycle irregularity, but this is a short-term adjustment, not infertility. The sources cited in support of the claim are either low-authority, commercially conflicted, or internally self-contradictory.
“Hormonal contraception, including birth control pills and hormonal IUDs, increases the risk of idiopathic intracranial hypertension.”
The best available evidence does not support this claim. A comprehensive meta-analysis published in Neurology in March 2026, along with earlier population-based case-control and large cohort studies, found no significant association between hormonal contraception — including birth control pills and hormonal IUDs — and idiopathic intracranial hypertension. Clinical guidance from neuro-ophthalmology specialists explicitly states there is no convincing causal evidence. The signals cited in support come from weaker study designs or apply only to specific products, not the class as a whole.
“The contraceptive pill has been officially classified as a top-tier carcinogen.”
The claim contains a kernel of truth: IARC classified combined oral contraceptives as Group 1 ("carcinogenic to humans") — its highest evidence category — back in 2005. However, "top-tier carcinogen" misleadingly implies extreme danger. Group 1 ranks the strength of scientific evidence, not the level of risk. The pill sits alongside processed meat in Group 1, not because they pose equal danger, but because evidence of some carcinogenic effect is strong. The claim also omits that the pill reduces the risk of ovarian and endometrial cancers and that absolute risk increases are small.